Recent Posts

anonymous said:

The failure here is not the recent performance that resulted in the stock decline but rather the decisions that were made years ago that severely underestimated the potential of semaglutide in obesity. Had the company really known what they had, we wouldn’t be in the no-win situation we are in now.

We would’ve had supply from the start. We would gained preference earlier. It would have taken years not months for Zepbound to take over.

Lars himself admitted as much a couple years ago during the peak of our supply issues. We are a diabetes company and we looked at Wegovy and obesity as a nice little add on. We totally underestimated the paradigm shifting potential that GLP-1 had.

Since that decision we made mis-step after mis-step. We thought our way of doing it was the right away and neglected to innovate and all the while Lilly just kept marching on.

You don’t need thousands of reps selling Wegovy. We launched it with a couple hundred. What you needed was supply. Support. Access. Innovation.

But now it’s all too late. Nothing can be done now to change the trajectory of both Ozempic and Wegovy. The best we can do is hope that CagriSema or another asset we’ve acquired can compete.

But again, Lilly is light years ahead of us in pipeline and their next generation meds look better than our own.

Love Novo as a company, but I fear for our future.

Click to expand...

anonymous said:

145k plus about 50 in bonus

Click to expand...